Brief: Acrux Ltd Says FDA Clears Regulatory Pathway For Female Testosterone Mdts
12/10/2026 02:36
BRIEF-Acrux Ltd Says FDA Clears Regulatory Pathway For Female Testosterone Mdts Oct 12 (Reuters) - Acrux Ltd ACR.AX:
FDA CLEARS REGULATORY PATHWAY FOR FEMALE TESTOSTERONE MDTS
FDA CONFIRMS ACRUX ELIGIBLE TO APPLY FOR 3-YEAR EXCLUSIVITY PERIOD
FDA CONFIRMS TWO 24-WEEK PHASE III TRIALS REQUIRED FOR EFFICACY IN HSDD
Further company coverage: ACR.AX
((Reuters.Briefs@thomsonreuters.com))
Recent news on Acrux
See all newsBrief: Acrux Ltd Says FDA Clears Regulatory Pathway For Female Testosterone Mdts
Brief: Acrux Licenses Lenzetto For Australian Market For A$5.4 Million
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Acrux Says Capital Gains Tax Exemptions Remain In Place For Acrux
Australia's Acrux jumps on placement to fund female testosterone program